| DIRECT COMPETITOR COMPARISON | |
| ILI | MYGN | NTY | Pvt1 | Industry | | Market Cap: | 27.28M | 2.30B | 2.53B | N/A | 62.33M | | Employees: | N/A | 869 | N/A | 1791 | 70 | | Qtrly Rev Growth (yoy): | -40.80% | 21.70% | 12.10% | N/A | 18.90% | | Revenue (ttm): | 9.20M | 341.68M | 2.58B | 16.50M1 | 12.73M | | Gross Margin (ttm): | 45.96% | 81.34% | 43.51% | N/A | 50.63% | | EBITDA (ttm): | -6.76M | 141.76M | 344.52M | N/A | -1.76M | | Oper Margins (ttm): | -92.41% | 38.86% | 10.68% | N/A | -3.83% | | Net Income (ttm): | -8.68M | 142.16M | 145.73M | N/A | N/A | | EPS (ttm): | -0.319 | 1.013 | 2.305 | N/A | N/A | | P/E (ttm): | N/A | 23.64 | 17.75 | N/A | 23.64 | | PEG (5 yr expected): | N/A | 0.72 | 0.87 | N/A | 1.36 | | P/S (ttm): | 2.93 | 6.79 | 1.01 | N/A | 3.09 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | NTY | | Weatherford Director Buys $1.6M
Fri, Nov 27 -
TheStreet.com | | • | MYGN | | Dream Stocks for Biotech Investors
Wed, Nov 25 -
at Motley Fool | | • | MYGN | | Heinz Lays It On Rich And Thick
Tue, Nov 24 -
at Forbes.com | | • | NTY | | NBTY President Kamil Sells $6.5M Worth
Fri, Nov 20 -
TheStreet.com | | • | NTY | | NBTY INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Thu, Nov 19 -
EDGAR Online | | • | MYGN | | Myriad Genetics to Present at the 21st Annual Piper Jaffray Health Care Conference
Tue, Nov 17 -
GlobeNewswire | | • | NTY | | Investors Find Fat Gains in Nutrition Stocks
Tue, Nov 17 -
Indie Research | | • | MYGN | | Zacks Bull and Bear of the Day Highlights: Infosys, Myriad Genetics Inc., American International Group, Citigroup, Bank of America
Mon, Nov 16 -
Zacks.com | | • | NTY | | NBTY To Webcast Presentation at Citigroup's 6th Annual Small/Mid Cap Conference
Mon, Nov 16 -
PR Newswire | | • | MYGN | | Myriad Genetics (MYGN)
Mon, Nov 16 -
Zacks.com | | • | MYGN | | J.C. Penney, Disney, Genzyme are big movers
Fri, Nov 13 -
AP | | • | MYGN | | Piper Jaffray Sees Pharma M&A Activity Continuing
Fri, Nov 13 -
Wall Street Transcript | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
0.0099 (1.18%) 
Competitors
